Back to Alzheimers Disease
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT01202994

NCT01202994
Completed Phase 2

Who may be able to join

Who might be able to join this trial:

  • You are currently taking part in a separate NIA (National Institute on Aging)-funded community study about memory and thinking skills in older adults aged 65 and over who live independently and do not have dementia (confirm with trial site)

Who may not be able to join:

  • You have a history of a brain or nervous system condition that affects memory or thinking, such as stroke, a serious head injury with loss of consciousness lasting more than 30 minutes, seizures, or similar conditions
  • You have been diagnosed with dementia
  • You have a current or past serious mental health condition, such as schizophrenia or bipolar disorder
  • You scored higher than 14 on a standard 30-question depression screening test for older adults
  • A brain scan (CT or MRI) has shown signs of stroke or an abnormal growth in the brain
  • You have a history of alcoholism or misuse of other substances
  • You are currently taking medications for memory/thinking, antipsychotics, or anti-seizure medications
  • You have previously had radiation treatment to the brain
  • You have a history of serious medical conditions such as cancer or AIDS
  • You have poorly controlled diabetes or your blood sugar was above 180 mg/dl on the day of a specific type of brain scan used in this study (called an FDG-PET scan)
  • You are currently pregnant

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Phase 2
Sponsor
University of Utah
Registry
clinicaltrials_gov
Start date
1 May 2011
Est. completion
1 May 2016

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Amyloid Deposition Obtained on a 18F-flutemetamol Brain Scan.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov